Skip to content

FDA Purchasing Power is on the Line

September 23, 2016

Earlier in September, Dr. Jeff Shuren, director of CDRH, presented to the Alliance membership at our quarterly meeting. It was an impressive presentation, providing us a sense of both the breadth and depth of CDRH activities. … READ MORE …

Advocacy at a Glance

September 23, 2016

Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA. … READ MORE …

What to Expect When You are Expecting a Lame Duck

September 16, 2016

The Senate’s website glossary defines a “lame duck” session as follows: … READ MORE …

Advocacy at a Glance

September 16, 2016

Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA. … READ MORE …

Omnibus, Minibus, or Any Type of Bus at All?

September 9, 2016

As can be seen on the chart below, the House and Senate are looking to provide FDA with $35 to $40 million in additional funding for FY 17. This would be lost under a long-term Continuing Resolution. … READ MORE …

Advocacy at a Glance

September 9, 2016

Advocacy at a Glance offers you the bullet point summary of current advocacy issues associated with the goals of the Alliance for a Stronger FDA. … READ MORE …

The Cost — and the Importance — of Public Attention

August 28, 2016

We never tire of pointing out that FDA regulates products that represent about 20% of all consumer spending. It is a mark of FDA’s centrality to the economy, as well as to the public’s health and well-being. … READ MORE …